Alpha IVF seeks accelerated transfer to Main Market
The fertility care group expects completion in the fourth quarter of 2026, subject to regulatory and shareholder approvals.
Alpha IVF Group has proposed switching its Bursa Malaysia listing from ACE to the Main Market through an accelerated process. In a bourse filing, the fertility care company said it expects to complete the move in the fourth quarter of 2026.
The proposal follows the accelerated route under the Securities Commission Malaysia’s Equity Guidelines. Alpha IVF said clearance is needed from the Securities Commission and Bursa Securities, alongside a shareholder vote at a general meeting. The principal adviser is UOB Kay Hian.
To support its eligibility, the company cited daily market capitalisation of between RM1.14 billion and RM1.35 billion during March 27 to Sept 28, 2026. Those values, calculated using volume-weighted average prices, exceeded the route’s RM1 billion threshold, it said.
Alpha IVF also reported meeting the profit requirements. Its aggregate audited Patmi reached RM164.02 million over three financial years ending May 31, 2026. Excluding RM15.12 million of other income put adjusted Patmi at RM148.90 million; the latest year contributed RM47.69 million.
The company said public ownership stood at about 31.69%, spread across 4,348 shareholders, compared with the Main Market’s 25% minimum. It also cited compliance with the Bumiputera equity requirement through an IPO allocation representing 14.50% of enlarged share capital.
The board said it expects stronger recognition among investors, including institutions. According to Alpha IVF, the transfer would not change earnings, gearing, net assets, share capital or substantial shareholders’ holdings.
